Skip to Content

Becton Dickinson & Co BDX

Morningstar Rating
$239.15 −2.09 (0.87%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Becton, Dickinson Should See Normalization in 2024 With Alaris' Return

After a tumultuous few years, Becton, Dickinson is undergoing course correction. The COVID-19 revenue windfall has been reinvested, which should lift the firm's core business growth in the upcoming years as the testing revenue fades. As Alaris has now returned to the market, the last remaining uncertainty has been resolved, although it is still to be seen whether the damage experienced by the franchise will be long-lasting or whether Alaris can regain its market-leading share rapidly.

Price vs Fair Value

BDX is trading at a 26% discount.
Price
$239.15
Fair Value
$763.00
Uncertainty
Medium
1-Star Price
$419.42
5-Star Price
$443.50
Economic Moat
Vzvhy
Capital Allocation
Vbbnnzy

Bulls Say, Bears Say

Bulls

The pharmaceutical business is the star of BD's portfolio. We expect robust growth to continue driven by demand for injectables.

Bears

BD's China medication delivery segment is facing competitive bidding challenges, which will pressure the overall growth in China in the upcoming years.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BDX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$241.24
Day Range
$238.84242.34
52-Week Range
$228.62287.32
Bid/Ask
$234.00 / $244.00
Market Cap
$69.09 Bil
Volume/Avg
829,240 / 1.7 Mil

Key Statistics

Price/Earnings (Normalized)
20.06
Price/Sales
3.56
Dividend Yield (Trailing)
1.54%
Dividend Yield (Forward)
1.59%
Total Yield
1.54%

Company Profile

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2023 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Large Value
Total Number of Employees
73,000

Competitors

Valuation

Metric
BDX
RHHBY
BAX
Price/Earnings (Normalized)
20.0612.0915.39
Price/Book Value
2.736.022.51
Price/Sales
3.563.151.42
Price/Cash Flow
21.2811.5914.66
Price/Earnings
BDX
RHHBY
BAX

Financial Strength

Metric
BDX
RHHBY
BAX
Quick Ratio
0.460.990.91
Current Ratio
1.081.351.48
Interest Coverage
4.1714.930.66
Quick Ratio
BDX
RHHBY
BAX

Profitability

Metric
BDX
RHHBY
BAX
Return on Assets (Normalized)
3.40%17.03%4.63%
Return on Equity (Normalized)
7.05%53.42%19.64%
Return on Invested Capital (Normalized)
5.04%26.30%6.97%
Return on Assets
BDX
RHHBY
BAX
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncGmgjr$136.2 Bil
ALC
Alcon IncPwtxc$41.8 Bil
CLPBY
Coloplast A/S ADRQtq$30.0 Bil
WST
West Pharmaceutical Services IncHfwc$26.2 Bil
RMD
ResMed IncLdkjsn$25.6 Bil
BAX
Baxter International IncXhnvylh$21.1 Bil
COO
The Cooper Companies IncSxdpzqs$18.8 Bil
HOLX
Hologic IncThblmm$17.4 Bil
TFX
Teleflex IncHbblp$10.6 Bil

Sponsor Center